GlassScriptPhysician profile
Faisal Suba
NPI 1598965998
$14,848.81
in general payments reported to CMS, 2019-2025
31 companies · $3,163 in 2025
The $3,163 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,595 · 2020: $56.00 · 2021: $635 · 2022: $1,445 · 2023: $1,865 · 2024: $2,091 · 2025: $3,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,118.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $5,314.36 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,595.37 | 2021-2025 | Ingrezza |
| Abbvie INC. | $1,423.15 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $1,156.54 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $864.98 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $826.67 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $814.60 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $406.37 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $390.09 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $358.08 | 2023-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $268.14 | 2021-2025 | Caplyta |
| Almatica Pharma LLC | $217.50 | 2023-2025 | Loreev Xr, Teriparatide |
| Lundbeck LLC | $202.72 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $198.03 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $140.49 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $124.65 | 2022-2024 | Azstarys |
| Bausch Health US, LLC | $97.07 | 2022-2025 | Aplenzin |
| Sage Therapeutics, LLC | $67.26 | 2024-2025 | Zurzuvae |
| Ironshore Pharmaceuticals INC. | $48.18 | 2024 | |
| Shire North American Group INC | $47.55 | 2019 | |
| Supernus Pharmaceuticals, INC. | $45.25 | 2023-2025 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $45.10 | 2023 | Quviviq |
| Brainsway USA INC | $32.00 | 2019 | |
| Indivior INC. | $31.60 | 2025 | Sublocade |
| Bioxcel Therapeutics, INC. | $29.73 | 2023 | Igalmi |
| Tris Pharma INC | $21.78 | 2023 | Dyanavel Xr |
| Acadia Pharmaceuticals INC | $19.40 | 2022 | |
| Neuronetics, INC. | $19.26 | 2023 | Neurostar Tms Therapy System |
| Eisai INC. | $14.90 | 2021 | |
| Owp Pharmaceuticals, INC. | $14.78 | 2025 | Subvenite |
| Medtronic USA, INC. | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Suba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.